Today: 8 June 2026
Browse Category

NASDAQ:MRNA 28 September 2025 - 23 November 2025

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna closed at $23.72 on Friday, near its 52-week low and down 38% over the past year. The company is now the most shorted stock in the S&P 500, with short interest near 18% as COVID vaccine sales collapse. Moderna has announced a new three-year strategy, $1.5 billion in new debt, and pipeline cuts while focusing on mRNA drugs for cancer and respiratory disease.
23 November 2025
·
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna shareholders are voting today on a one-time stock option exchange for non-executive employees, which could cut outstanding options by about 3.44 million shares. BNY Mellon reduced its MRNA stake by 16% last quarter, while Campbell & CO opened a new position. MRNA shares are trading higher intraday as investors await the vote and assess recent earnings.
12 November 2025
·
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna shares rose mid-session Tuesday after UBS cited 2026 upside tied to cost cuts and pipeline progress. Redburn Atlantic lowered its price target to $36, while Bernstein reiterated a $25 target and neutral view, highlighting the need for further expense reductions. The moves follow last week’s Q3 report, which showed a narrower loss and tighter 2025 guidance.
11 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

U.S. stocks opened lower Thursday as investors weighed weak private jobs data and mixed earnings. Challenger reported over 150,000 announced layoffs in October, the highest for the month in more than 20 years. The dollar fell for a second day as traders raised odds of a December Fed rate cut. Qualcomm and DoorDash dropped on company risks; Datadog and Moderna gained on strong results.
6 November 2025
······
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna reported Q3 2025 revenue of $1.02 billion and a GAAP loss of $0.51 per share, both ahead of analyst forecasts, driven by $971 million in COVID-19 vaccine sales. The company narrowed its full-year revenue outlook to $1.6–$2.0 billion, cut operating-expense guidance by $700 million, and raised its year-end cash target. Shares rose pre-market but traded unevenly during the session.
6 November 2025
··
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

U.S. equity futures edged lower early Thursday as Asian markets rebounded on strong U.S. data, while European shares slipped. Treasury yields rose and the dollar stayed firm. Key U.S. data releases include jobless claims and productivity at 8:30 a.m. ET. Qualcomm, Arm, and Snap moved pre-market on earnings, with several major reports due before and after the bell.
6 November 2025
········
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna shares surged 12% to near $27.50 on Oct. 30, 2025, after reports of takeover talks with a large drugmaker. The rally follows a STAT News report on possible deals, but Moderna declined comment. Despite gains, the stock remains down about 37% year-to-date. Recent FDA approvals include updated COVID and RSV vaccines, but falling COVID demand has cut 2025 revenue and forced cost reductions.
30 October 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 19.10.2025

China blocked Ant Group and JD.com from launching stablecoins, reinforcing state control over digital currency. U.S. stock futures rose ahead of a packed earnings week, with Tesla and Netflix among companies reporting. IonQ reported Q3 revenue up 102% to $12.4 million but posted a $52.5 million net loss, while Nvidia posted record Q3 revenue of $35.1 billion.
19 October 2025
···········
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna shares rose 5% to $28 but remain down 35% in 2024 and nearly 80% below last year’s level. COVID vaccine sales have collapsed from $18.9 billion in 2022 to $3.1 billion, and Q2 revenue fell 41% to $142 million. The company cut its 2025 revenue forecast and is laying off 10% of staff. Early data from an experimental cancer vaccine showed a 24% tumor response rate in advanced melanoma.
16 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia will invest up to $100 billion to build 10 gigawatts of AI data centers for OpenAI, with the first 1 GW due by late 2026. The US cybersecurity agency issued an emergency directive after hackers breached at least one federal agency via Cisco firewall flaws, affecting hundreds of devices. The FDA approved Eli Lilly’s new breast cancer drug Inluriyo. The SEC loosened ETF rules, opening the door for new crypto ETFs.
28 September 2025
·········
1 2 3

Stock Market Today

  • Is NVIDIA (NVDA) a Good Buy Amid AI Growth and High Valuation?
    June 8, 2026, 2:12 PM EDT. NVIDIA Corporation (NVDA) trades at $205.10 with a trailing P/E of 31.41 and forward P/E of 23.42 as of June 5. Bulls argue NVDA offers value investing in growth, citing expected revenue of $78.8 billion and net income of $43.5 billion in Q1 fiscal 2027. Management forecasts profits may exceed $200 billion in 2027, up over 70% from 2025. Despite its size, market skepticism on sustaining rapid growth creates a potential undervaluation. Demand for Nvidia's AI infrastructure remains strong, constrained by supply, not customer appetite. Past bullish outlooks focused on NVDA's AI dominance, competitive moat via CUDA technology, expanding markets, and solid valuation amid moderating growth. The firm is positioned near record U.S. corporate profitability levels with continued sequential growth guidance.

Latest articles

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

ASML Sets New European Valuation Record; Broadcom Shows Risks in AI

8 June 2026
ASML’s market value soared to a European record of $691.8 billion as analysts raised estimates for its EUV machine output, driving U.S. shares up 7.1% after JPMorgan and Morgan Stanley hiked price targets, with investors betting on ASML’s control of critical chipmaking tools amid surging AI demand and factory expansions planned for 2026.
Meta $145 Billion AI Push Faces Snag With Wall Street

Meta $145 Billion AI Push Faces Snag With Wall Street

8 June 2026
Meta shares fell 0.8% to $587.97 Monday after reports the company may sell tens of billions in new stock to fund AI infrastructure, raising investor concerns about dilution as capital spending soars and AI financing shifts from earnings to equity markets; Meta has not hired banks and may still consider other financing options.
Palantir’s $200 Target Meets Doubts on AI Growth

Palantir’s $200 Target Meets Doubts on AI Growth

8 June 2026
Palantir shares steadied at $135.73 after a volatile week, as investors weighed 85% Q1 revenue growth and a raised 2026 forecast against a steep 96x forward earnings valuation, with analysts warning that any slowdown in U.S. commercial or government revenue, or a shift in AI sentiment, could sharply impact the stock’s high multiple.
Go toTop